Evaluating medication effects outside of clinical trials: new-user designs.
about
The prevalence and cost of unapproved uses of top-selling orphan drugsADHD drugs and serious cardiovascular events in children and young adultsADHD medications and risk of serious cardiovascular events in young and middle-aged adults.Opioid analgesics and the risk of fractures in older adults with arthritisDifficulties in demonstrating superiority of an antibiotic for multidrug-resistant bacteria in nonrandomized studiesThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesDepression, antidepressants, and bone health in older adults: a systematic reviewColorectal cancer after start of nonsteroidal anti-inflammatory drug useProton pump inhibitors and risk of periampullary cancers--A nested case-control studyCoffee consumption and incidence of lung cancer in the NIH-AARP Diet and Health StudyLong-term prescription of α-blockers decrease the risk of recurrent urolithiasis needed for surgical intervention-a nationwide population-based studyAssociation between extent of thiazolidinedione exposure and risk of acute myocardial infarctionObservational comparative effectiveness studies of drug therapies: high-quality answers or important clinical questions?: comment on "Comparative effectiveness of 2 β-blockers in hypertensive patients"Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort studyAngiotensin receptor blockers and risk of cancer: cohort study among people receiving antihypertensive drugs in UK General Practice Research DatabasePregnancy and virologic response to antiretroviral therapy in South AfricaThe Value of Patient-Centred Registries in Phase IV Drug SurveillanceA tutorial on the use of instrumental variables in pharmacoepidemiology.Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility.Observational data for comparative effectiveness research: an emulation of randomised trials of statins and primary prevention of coronary heart disease.Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership.A risk prediction model for smoking experimentation in Mexican American youth.Use of data from multiple registries in studying biologic discontinuation: challenges and opportunitiesAn analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease.Assessing potentially time-dependent treatment effect from clinical trials and observational studies for survival data, with applications to the Women's Health Initiative combined hormone therapy trial.Misclassification in administrative claims data: quantifying the impact on treatment effect estimates.Methodological framework to identify possible adverse drug reactions using population-based administrative data.Predictors of prevalent statin use among older adults identified as statin initiators based on Medicare claims data.Use of prescription drug claims data to identify lipid-lowering medication exposure in pharmacoepidemiology studies: potential pitfalls.Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorderDistinguishing patterns in the dynamics of long-term medication use by Markov analysis: beyond persistenceHigh-dimensional propensity score adjustment in studies of treatment effects using health care claims dataValidation of diagnostic codes for outpatient-originating sudden cardiac death and ventricular arrhythmia in Medicaid and Medicare claims data.Evidence of potential bias in a comparison of β blockers and calcium channel blockers in patients with chronic obstructive pulmonary disease and acute coronary syndrome: results of a multinational study.Confounder summary scores when comparing the effects of multiple drug exposuresThe new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 monthsNonexperimental comparative effectiveness research using linked healthcare databasesDoes the association between adherence to statin medications and mortality depend on measurement approach? A retrospective cohort studyImpact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults.Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.
P2860
Q21134770-96E2FE7C-E18C-46A6-9BF0-7AD9685F4A04Q22250876-3B548CB1-3C93-4CB9-A1D0-70153CCD4A1BQ22253017-63E82C06-0594-44B2-A2A7-D1CEEA3779BEQ24607425-1C0B8FD5-4B61-4C5D-A01E-005B577861E6Q26863059-CA5AE0AB-DEA4-46D7-A5C1-1F662410C512Q26999933-BA3B13A1-BDEA-4BBF-8A80-E9AC53D80B3CQ27010527-A7FE57C3-02CE-46D1-9A56-2692CDBC8AB1Q28218715-D321F6DB-27B5-4078-912F-B589DBB3382FQ28385784-69642C30-0073-47A0-8F01-19CB96B49C98Q28387946-26E365B5-473C-4257-B612-B34D6BFB7435Q28391733-1C50392E-03E8-4B2D-A2B8-6591E57F9170Q28396990-D5AC559A-C6B9-40CA-A4C2-5405B6F7E583Q28703603-0E94EBA3-DC47-4634-A662-1BF1A3E093C7Q28729087-1D3DDCE6-810A-407E-B2A8-31F29F10D2FBQ28730234-E9144554-3C9F-4E48-9EF2-3637B1B9BA29Q28741879-7050559B-A587-4770-AE3B-326E8980A0BDQ29395899-058B69BB-45AA-4BDA-8423-BC5ACE9CF42AQ30235546-37AEB364-FE8A-47F2-B250-3E29E00D0913Q30243926-CEA19147-3918-433F-803F-900870EDD679Q30538243-B099C7E6-FEA9-4A46-B64E-86042EA92FDBQ30570859-E6BCA0C5-E834-4A80-9EE6-0D1F172D7B5BQ30588859-8EEC91CB-E911-4478-8869-FA49A2469B98Q30678187-002C14DD-161D-4591-B94C-61D840FB2B8EQ30696956-8BD0FA5D-6CB9-45DD-8EA7-D3C59BB9D4B0Q30894392-1546813D-A25A-40E7-86FA-8E8BE6027309Q30974376-70215147-E9F2-4C50-A02A-83684FCBAFFCQ30980862-40DBD019-6F86-4088-AADC-98AFEFBC51DCQ31060524-709CB963-2473-4510-8954-E10A5689B7A5Q31090652-DBC24D2A-67AB-48BD-8401-82495D9CDB11Q33160890-53FDF18D-FA72-4FF3-B9A3-1D57F104BC63Q33290343-E5C76EAA-9DEC-421C-9B4E-D7ACB08A5385Q33457966-C3ECB8ED-8B8B-4ACE-B532-D20EBF6F018AQ33511608-7B0FA8F7-9B8F-48D2-9E8A-B6404B682D31Q33552609-A09B1F1D-2897-4FD4-8D04-124FCC4B80E5Q33566259-1677B80F-2D9F-4208-9B35-7B36C98C397CQ33568429-2461562F-F2F5-434D-9EB1-E2A51DBF0F03Q33576469-12D3A1B4-7010-4794-B54A-FA5D1D02F420Q33582496-56B93B4C-48B3-42F3-9AC7-99B6969D4603Q33601225-E2D493C7-4300-4A2C-91CA-A24E21FC64E4Q33625546-3CEE269C-F424-40F9-88FC-03EEC045E7D0
P2860
Evaluating medication effects outside of clinical trials: new-user designs.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Evaluating medication effects outside of clinical trials: new-user designs.
@en
Evaluating medication effects outside of clinical trials: new-user designs.
@nl
type
label
Evaluating medication effects outside of clinical trials: new-user designs.
@en
Evaluating medication effects outside of clinical trials: new-user designs.
@nl
prefLabel
Evaluating medication effects outside of clinical trials: new-user designs.
@en
Evaluating medication effects outside of clinical trials: new-user designs.
@nl
P356
P1476
Evaluating medication effects outside of clinical trials: new-user designs.
@en
P2093
Wayne A Ray
P304
P356
10.1093/AJE/KWG231
P407
P577
2003-11-01T00:00:00Z